Search

Your search keyword '"Ixazomib"' showing total 87 results
Start Over Descriptor "Ixazomib" Publication Type News
87 results on '"Ixazomib"'

1. NHS calls on 'Covid-friendly' drugs to cut cancer backlog

Subjects
Venetoclax, Ixazomib, Coronaviruses, Cancer -- Drug therapy, Atezolizumab, Enzalutamide, Chemotherapy, Drug approval, General interest
Abstract

Byline: Sarah Knapton Science editor THE NHS is to roll out 'covid-friendly' cancer drugs in an effort to beat the treatment backlog which is putting lives at risk. Cancer services [...]

Published
2020

2. Seattle Cancer Care Alliance to Present New Research at 62nd Annual Meeting of the American Society of Hematology

Subjects
Ixazomib, Axicabtagene ciloleucel, Cancer, Cancer research, Carboplatin, Immunotherapy, Pembrolizumab, Nilotinib, Associations, Tranexamic acid, Antineoplastic agents, Tisagenlecleucel, Business, Business, international
Abstract

Clinicians to highlight research on immunotherapies and various hematological malignancies. SEATTLE -- Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, announced [...]

Published
2020

6. Medicinal Products Containing Ixazomib, Alectinib, Lenvatinib, Venetoclax

Subjects
Venetoclax, Ixazomib, Lenvatinib, Alectinib, Business, international
Abstract

Contract notice: Medicinal products containing ixazomib, Alectinib, Lenvatinib, Venetoclax Name of the active substance, strength and size of the package: Ixazomib citrate 4 MG CPS DUR 3 (3X1), ATC: L01XX50, [...]

Published
2020

7. Takeda returns to CIIE, commits to China

Subjects
Brentuximab vedotin, Lanadelumab -- Planning, Ixazomib, Vedolizumab, Velaglucerase alfa, Icatibant, Company business planning, Business, international, Law
Abstract

Takeda, a global values-based, R&D-driven biopharmaceutical company, is returning to the China International Import Expo (CIIE) this year to showcase its innovative medicines and breakthrough therapies, and to demonstrate its [...]

Published
2020

8. Feasibility of In-Class Transition to Oral Ixazomib-Lenalidomide-Dexamethasone in Community-Based MM Population

Subjects
Ixazomib, Angiogenesis inhibitors, Medical centers, Central nervous system depressants, Multiple myeloma, Lenalidomide, Dexamethasone, Business, international, Law
Abstract

The in-class transition to oral ixazomib-lenalidomide-dexamethasone appears feasible in randomized clinical trial ineligible patients with multiple myeloma (MM) in US community oncology centers despite the range of comorbidities, according to [...]

Published
2020

9. Takedas Ninlaro misses primary goal in multiple myeloma trial

Subjects
Ixazomib, Multiple myeloma, Dexamethasone -- Product development, Business, international, Law, Ninlaro (Medication) -- Product development
Abstract

Takeda Pharmaceutical has reported results from the Phase III TOURMALINE-MM2 clinical trial of Ninlaro (ixazomib) plus lenalidomide and dexamethasone to treat multiple myeloma. The combination was compared to lenalidomide and [...]

Published
2020

10. Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO[TM] (ixazomib) in Newly Diagnosed Multiple Myeloma

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Lithium compounds -- Product development, Multiple myeloma, Stem cells, Pharmaceutical industry -- Product development, Dexamethasone -- Product development, Business, Business, international, Ninlaro (Medication) -- Product development
Abstract

TOURMALINE-MM2 Data Presented Virtually at the Society of Hematologic Oncology (SOHO) Eighth Annual Meeting CAMBRIDGE, Mass. & OSAKA, Japan -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') today announced results from [...]

Published
2020

11. Global Small Molecule Cancer Drugs Market 2020-2026: Expected to Double in Next 6 Year Period Reaching $130 Billion, Driven by New Drug Launches & Dynamic Clinical Pipeline

Subjects
Ixazomib, Pixantrone, Kinase inhibitors, Alitretinoin, Belinostat, Enzyme inhibitors, Alectinib, Levoleucovorin, Zoledronic acid, Fluciclovine, Palbociclib, Omacetaxine mepesuccinate, BCR-ABL tyrosine kinase inhibitors, Idelalisib, Olaparib, Nintedanib, Fluoxymesterone, Antineoplastic agents, Banking, finance and accounting industries, Business
Abstract

Dublin, Sep 01, 2020 (GLOBE NEWSWIRE via COMTEX) -- The 'Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026' report has been added to ResearchAndMarkets.com's [...]

Published
2020

13. NHS to roll out 'Covid-friendly' cancer drugs to clear backlog of treatment; Cancer services have been dramatically impacted by lockdown, and the reallocation of health resources towards coronavirus

Subjects
Venetoclax, Ixazomib, Coronaviruses, Atezolizumab, Enzalutamide, Chemotherapy, Drug approval, General interest, News, opinion and commentary
Abstract

Byline: Sarah Knapton, Science Editor The NHS is to roll out 'covid-friendly' cancer drugs in bid to beat the backlog of treatment which is putting lives at risk. Cancer services [...]

Published
2020

16. Martyn Day ask the Secretary of State for Health and Social Care, what treatment options are available to patients with multiple myeloma who have become refractory to previous lines of therapy

Subjects
Carfilzomib, Ixazomib, Multiple myeloma -- Care and treatment, Daratumumab, Business, international
Abstract

London: UK Parliament has issued the following written answer: Answered by: Jo Churchill Answered on: 01 July 2020 For patients who have received previous lines of treatment, the National Institute [...]

Published
2020

17. Ixazomib 4mg

Subjects
Ixazomib, Business, international
Abstract

Contract awarded for Ixazomib 4mg Date of conclusion of the contract: 25-05-2020 Contract price: 7. 781,00 Deadline: 20 days Place of execution - Country, District, Municipality: Portugal, porto, porto Contractor [...]

Published
2020

18. Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Multiple myeloma, Stem cells, Pharmaceutical industry -- Product development, Stem cell transplantation, Business, international, Law, Ninlaro (Medication) -- Product development
Abstract

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced it will orally present the results of two studies at the 25th Congress of the European Hematology Association (EHA). Presentations are available [...]

Published
2020

19. Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO[TM] (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy

Subjects
Takeda Pharmaceutical Company Ltd., Clinical trials, Ixazomib, Lithium compounds, Multiple myeloma, Stem cells, Pharmaceutical industry, Stem cell transplantation, Business, Business, international, Ninlaro (Medication)
Abstract

Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation Real-World Community-Based Trial (US [...]

Published
2020

20. Active Biotech provides status update in the portfolio projects

Subjects
Active Biotech AB -- Planning, Durvalumab -- Planning, Financial markets, Biotechnology, Ixazomib, Company business planning, Telecommunications industry
Abstract

(GlobeNewswire) - Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated [...]

Published
2020

21. Active Biotech provides status update in the portfolio projects

Subjects
Active Biotech AB -- Planning, Durvalumab -- Planning, Financial markets, Biotechnology, Ixazomib, Company business planning, Business, international, Law
Abstract

(GlobeNewswire) - Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early February. This abbreviated [...]

Published
2020

22. Active Biotech provides status update in the portfolio projects

Subjects
Active Biotech AB -- Planning, Durvalumab -- Planning, Financial markets, Biotechnology, Ixazomib, Biotechnology industries -- Planning, Company business planning, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Lund, June 3, 2020 - Active Biotech (Nasdaq Stockholm: ACTI) today provides a status update in the projects following the new direction communicated in early [...]

Published
2020

23. Ninlaro Combo Fails to Extend New Myeloma Patients Survival Without Disease Worsening

Subjects
Ixazomib, Multiple myeloma -- Development and progression -- Patient outcomes, Stem cells, Dexamethasone, Stem cell transplantation, Death, Time, Lenalidomide, Glucocorticoids, Lithium compounds, Diseases, Business, international, Law, Ninlaro (Medication), Revlimid (Medication)
Abstract

A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people with newly diagnosed multiple myeloma who are ineligible [...]

Published
2020

24. Japan,United States : Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Ixazomib, Lithium compounds -- Product development, Multiple myeloma, Pharmaceutical industry -- Product development, Dexamethasone, Lenalidomide, Glucocorticoids, Prescription writing, Business, international, Ninlaro (Medication)
Abstract

Takeda Pharmaceutical Company Limited (Takeda) announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple [...]

Published
2020

25. Takedas Ninlaro falls short in first line multiple myeloma

Subjects
Bristol-Myers Squibb Co., Ixazomib, Chemotherapy, Multiple myeloma, Daratumumab, Pharmaceutical industry, Lithium compounds, Business, international, Law, Ninlaro (Medication), Revlimid (Medication), Darzalex (Medication)
Abstract

Takedas Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgenes Revlimid and chemo in newly diagnosed multiple myeloma. The data from the TOURMALINE-MM2 [...]

Published
2020

26. TOURMALINE-MM2 study on NINLARO fails to deliver desired results

Subjects
Ixazomib, Lithium compounds, Multiple myeloma, Dexamethasone, Lenalidomide, Glucocorticoids, Business, international, Law, Ninlaro (Medication)
Abstract

Takeda Pharmaceutical said that the phase 3 TOURMALINE-MM2 study evaluating the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in certain multiple myeloma population could not deliver the desired results. [...]

Published
2020

27. Takedas multiple myeloma drug misses PFS endpoint in Phase III trial

Subjects
United States. Food and Drug Administration, Clinical trials, Ixazomib, Multiple myeloma -- Drug therapy, Drug approval, Dexamethasone -- Product development, Pharmaceutical industry, Lenalidomide, Glucocorticoids, Lithium compounds, Business, international, Law, Ninlaro (Medication)
Abstract

Takeda Pharmaceutical Company has reported that its oral multiple myeloma drug Ninlaro (ixazomib) missed the progression-free survival (PFS) endpoint in the TOURMALINE-MM2 study. The study was designed to evaluate the [...]

Published
2020

29. Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Ixazomib, Lithium compounds -- Product development, Multiple myeloma, Pharmaceutical industry -- Product development, Dexamethasone, Lenalidomide, Glucocorticoids, General interest, News, opinion and commentary, Ninlaro (Medication)
Abstract

CAMBRIDGE: Takeda Pharmaceutical Company Limited has issued the following press release: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition [...]

Published
2020

30. Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Ixazomib, Lithium compounds -- Product development, Multiple myeloma, Pharmaceutical industry -- Product development, Dexamethasone, Lenalidomide, Glucocorticoids, Prescription writing, Business, international, Law, Ninlaro (Medication)
Abstract

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in newly [...]

Published
2020

31. Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Ixazomib, Lithium compounds -- Product development, Multiple myeloma, Pharmaceutical industry -- Product development, Dexamethasone -- Product development, Lenalidomide, Glucocorticoids, Prescription writing, Business, Business, international, Ninlaro (Medication)
Abstract

CAMBRIDGE, Mass. & OSAKA, Japan -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO[TM] (ixazomib) to lenalidomide [...]

Published
2020

32. Karyopharm posts positive data from Phase III trial of multiple myeloma drug

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Carfilzomib, Ixazomib, Pomalidomide, Multiple myeloma -- Drug therapy, Daratumumab, Pharmaceutical industry -- Product development, Drug approval, Steroids (Organic compounds), Dexamethasone, Glucocorticoids, Bortezomib, Business, international, Law, Velcade (Medication), Xpovio (Medication)
Abstract

A company that last year won accelerated Food and Drug Administration approval for a drug to treat multiple myeloma patients who have received numerous prior therapies will seek to expand [...]

Published
2020

33. Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Amyloidosis, Lithium compounds -- Product development, Pharmaceutical industry -- Product development, Dexamethasone -- Product development, Recurrence (Disease), Glucocorticoids, General interest, News, opinion and commentary, Ninlaro (Medication)
Abstract

CAMBRIDGE: Takeda Pharmaceutical Company Limited has issued the following press release: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral [...]

Published
2019

34. 191g004039 - Ixazomib 4 Mg Caps

Subjects
Ixazomib, Contractors, Business, international
Abstract

Contract awarded for 191g004039 - ixazomib 4 mg caps Date of conclusion of the contract: 13-11-2019 Contract price: 15. 561,96 Deadline: 48 days Place of execution - Country, District, Municipality: [...]

Published
2019

35. Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Amyloidosis, Lithium compounds -- Product development, Pharmaceutical industry -- Product development, Dexamethasone -- Product development, Recurrence (Disease), Glucocorticoids, Business, international, Law, Ninlaro (Medication)
Abstract

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting [...]

Published
2019

36. Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ(r) Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients

Subjects
Biotechnology, Ixazomib, Medical tests, Axicabtagene ciloleucel, Daratumumab, Cancer patients, Obinutuzumab, Antineoplastic agents, Lymphocytic leukemia, Bendamustine, Carfilzomib, Venetoclax, Immune system, Backup software, Ibrutinib, Acute lymphocytic leukemia, General interest, News, opinion and commentary
Abstract

Washington: Adaptive Biotechnologies has issued the following press release: Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system [...]

Published
2019

37. Ixazomib 4 Mg Caps

Subjects
Ixazomib, Contractors, Business, international
Abstract

Contract awarded for Ixazomib 4 mg caps Date of conclusion of the contract: 27-11-2019 Contract price: 15. 561,96 Deadline: 32 days Place of execution - Country, District, Municipality: Portugal, autonomous [...]

Published
2019

38. Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ(R) Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients

Subjects
Biotechnology, Ixazomib, Medical tests, Axicabtagene ciloleucel, Daratumumab, Leukemia, Cancer patients, Obinutuzumab, Lymphomas, Antineoplastic agents, Cancer research, Bendamustine, Tumors, Carfilzomib, Venetoclax, Immune system, Backup software, Ibrutinib, Non-Hodgkin's lymphomas, Banking, finance and accounting industries, Business
Abstract

SEATTLE, Dec 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- Research and real-world evidence support the use across a range of leukemias and lymphomas and demonstrate utility in multiple tissue types, [...]

Published
2019

39. Japan,United States : Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Lithium compounds -- Product development, Multiple myeloma -- Care and treatment, Stem cells, Pharmaceutical industry -- Product development, Stem cell transplantation, Business, international, Ninlaro (Medication)
Abstract

Takeda Pharmaceutical Company Limited ('Takeda') announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO [...]

Published
2019

40. Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Multiple myeloma -- Care and treatment, Stem cells, Pharmaceutical industry -- Product development, Stem cell transplantation, Lithium compounds, General interest, News, opinion and commentary, Ninlaro (Medication)
Abstract

Osaka: Takeda Pharmaceutical Company Limited (TKPYY) has issued the following press release: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ('Takeda') today announced the randomized, Phase 3 TOURMALINE-MM4 study met its [...]

Published
2019

42. Delivery Of The Drug (inn: Ixazomib)

Subjects
Ixazomib, Business, international
Abstract

Tenders are invited for delivery of the drug (inn: ixazomib) Given in the technical specifications Document Purchase Start date : 11 Jul 2019 Major organization : STATE PUBLIC INSTITUTION 'MANAGEMENT [...]

Published
2019

43. Takeda's Ninlaro Drug Overview 2019 with Sales by Country (2017-2026)

Subjects
Johnson & Johnson, Ixazomib, Multiple myeloma, Pharmaceutical industry, Proteins, Apoptosis, Tumors, Bortezomib, General interest, News, opinion and commentary, Ninlaro (Medication)
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Ninlaro' report has been added to ResearchAndMarkets.com's offering. Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the [...]

Published
2019

44. Takeda's Ninlaro Drug Overview 2019 with Sales by Country (2017-2026) - ResearchAndMarkets.com

Subjects
Johnson & Johnson, Ixazomib, Multiple myeloma, Pharmaceutical industry, Proteins, Apoptosis, Tumors, Bortezomib, Business, Business, international, Ninlaro (Medication)
Abstract

DUBLIN -- The 'Ninlaro' report has been added to ResearchAndMarkets.com's offering. Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the [...]

Published
2019

45. Takeda's Ninlaro Drug Overview 2019 with Sales by Country (2017-2026)

Subjects
Johnson & Johnson, Ixazomib, Pharmaceutical industry, Proteins, Apoptosis, Tumors, Bortezomib, Business, Business, international, Ninlaro (Medication)
Abstract

M2 PRESSWIRE-June 27, 2019-: Takeda's Ninlaro Drug Overview 2019 with Sales by Country (2017-2026) (C)1994-2019 M2 COMMUNICATIONS RDATE:27062019 The 'Ninlaro' report has been added to ResearchAndMarkets.com's offering. Ninlaro (ixazomib; Takeda) [...]

Published
2019

46. Czechia Tenders Contract Notice: Fakultni nemocnice Plzen Issues contract notice for 'Czechia-Plzen: Antineoplastic and immunomodulating agents'

Subjects
Ixazomib, Brodalumab, Purchasing, Domain names, Email, Contract agreement, General interest, News, opinion and commentary, European Union
Abstract

Plzen: Fakultni nemocnice Plzen has issued requirement for 'Czechia-Plzen: Antineoplastic and immunomodulating agents' Czechia-Plzen: Antineoplastic and immunomodulating agents 2019/S 112-274462 Contract notice Supplies Legal Basis: Directive 2014/24/EU Section I: Contracting [...]

Published
2019

47. EMA|PDCO|8432|2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO)

Subjects
Fidaxomicin, Ixazomib, Niraparib, Rolapitant, Ruxolitinib, Denosumab, Umeclidinium bromide, Tolvaptan, Avibactam, Indacaterol, Ivacaftor, Nivolumab, Lacosamide, Sodium zirconium cyclosilicate, Tafenoquine, Brivaracetam, Golimumab, Pembrolizumab, Obeticholic acid, Alirocumab, Vilanterol, Durvalumab, Ezetimibe, Treprostinil, Saxagliptin, Dapagliflozin, Erenumab, Health, Drugs, Business, international
Abstract

Amsterdam: European Medicines Agency has issued the following document: Draft agenda for the meeting on 23-26 January 2018 Chair: Dirk Mentzer - Vice-Chair: Koenraad Norga 23 January 2018, 14:00- 19:00, [...]

Published
2019

48. EMA|PDCO|66082|2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO)

Subjects
Ezetimibe, Ixazomib, Belatacept, Tocilizumab, Crisaborole, Obeticholic acid, Dasatinib, Lubiprostone, Drugs, Health, Business, international
Abstract

Amsterdam: European Medicines Agency has issued the following document: Draft agenda for the meeting on 20-23 February 2018 Chair: Dirk Mentzer - Vice-Chair: Koenraad Norga 20 February 2018, 14:00- 17:00, [...]

Published
2019

49. Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Amyloidosis, Lithium compounds -- Product development, Pharmaceutical industry -- Product development, Physicians, Recurrence (Disease), Medical care quality, Dexamethasone, Glucocorticoids, General interest, News, opinion and commentary, Ninlaro (Medication)
Abstract

CAMBRIDGE: Takeda Pharmaceutical Company Limited has issued the following press release: Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with [...]

Published
2019

50. Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis

Subjects
Takeda Pharmaceutical Company Ltd. -- Product development, Clinical trials, Ixazomib, Amyloidosis, Lithium compounds -- Product development, Medical care quality, Pharmaceutical industry -- Product development, Dexamethasone -- Product development, Physicians, Recurrence (Disease), Glucocorticoids, Business, international, Ninlaro (Medication)
Abstract

Cambridge, June 6 -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results